简介：ObjectivesToevaluateantihypertensiveefficiencyandsafetyofanewdomesticofL-&N-typeCa^2+antagonist-eilnidipinewithimidaprilasapositivecontrol.MethodsAfter2weeks'placebowashingout,22patientsweretreatedwitheilnidipine5mgdailyand27patientsweretreatedwithimidapril5mgdaily.4weekslater,ifpatient'ssittingdiastolicbloodpressureisover90mmHg,his/herdosagewasdoubledforanother4weeks,theothersmeasuringupremainedtheirdosageunchangedforanother4weeks.Bloodpressure,heartrate,bloodandurineroutineexamination,serumglucose,serumchemicalexaminationincludingtotalcholesterol,triglyceride,HDL,LDL,transaminase,creatineetcandsidereactionswererecordedbeforeandafterthetrial.Datawereanalyzedstatistically.ResultsAfter8weeks'treatment,bloodpressurewassignificantlydecreased(P<0.05)inbothgroups,andthetwomedicineshadsimilarantihypertensiveeffects.Furthermore,thereducingofheartratewasstatisticallysignificantcomparedwithbaseline(P<0.01)inthecilnidipinegroup,butnotintheimidaprilgroup.Thenegativechronotropiceffectofcilnidipinehadlittleeffectoncontinuingthetherapy.Therewerenochangesonbloodandurineroutineexaminationandserumlipid,serumglucose,creatine,transaminaseandetcinbothgroups.Theirsidereactionsweremildandwell-tolerated.ConclusionsCilnidipinehasacon-vincingantihypertensiveeffectsimilartothatofimi-dapril.Especiallycilnidipinemaybeadministeredtopatientswithrelativelymildtachycardia.

简介：AbstractBackground:Generic drugs are bioequivalent to their brand-name counterparts; however, concerns still exist regarding the effectiveness and safety of generic drugs because of small sample sizes and short follow-up time in most studies. The purpose of this study was to evaluate the long-term antihypertensive efficacy, cost-effectiveness and cardiovascular outcomes of generic drugs compared with brand-name drugs.Methods:In a multicenter, community-based study including 7955 hypertensive patients who were prospectively followed up for an average of 2.5 years, we used the propensity-score-matching method to match the patients using brand-name drugs to those using generic drugs in a ratio of 1:2, 2176 patients using brand-name drugs and 4352 patients using generic drugs.Results:There were no significant differences between generic drugs and brand-name drugs in blood pressure (BP)-lowering efficacy, BP control rate, and cardiovascular outcomes including coronary heart disease and stroke. The adjusted mean (95% confidence interval [CI]) of systolic BP (SBP)-lowering was -7.9 mmHg (95% CI, -9.9 to -5.9) in the brand-name drug group and -7.1 mmHg (95% CI, -9.1 to -5.1) in the generic drug group after adjusting for age, sex, body mass index, number of antihypertensive drugs and traditionally cardiovascular risk factors. Among patients aged <60 years, brand-name drugs had a higher BP control rate (47% vs. 41%; P = 0.02) and a greater effect in lowering SBP compared with generic drugs, with the between-group difference of 1.5 mmHg (95% CI, 0.2-2.8; P = 0.03). BP control rate was higher in male patients using brand-name drugs compared with those using generic drugs (46% vs. 40%; P = 0.01). Generic drugs treatment yielded an average annual incremental cost-effectiveness ratio of $315.4 per patient per mmHg decrease in SBP compared with brand-name drugs treatment.Conclusions:Our data suggested that generic drugs are suitable and cost-effective in improving hypertension management and facilitating public health benefits, especially in low- and middle-income areas.

简介：1-(2,6-Dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)-propanehydrochloride(DDPH)isanovelantihypertensiveagentbasedonstructuralcharacteristicsofmexiletineandverapamine.WeinvestigatedtheeffectofDDPHonvasodilatationandneuroprotectioninaratmodelofcerebralischemiainvivo,andarabbitmodelofisolatedbasilararteriesinvitro.OurresultsshowthatDDPH(10mg/kg)significantlyincreasedhippocampalbloodflowinvivoincerebralischemicrats,andexerteddose-dependentrelaxationofisolatedbasilararteriescontractedbyhistamineorKClintheinvitrorabbitmodel.DDPH(3×10–5M)alsoinhibitedhistamine-stimulatedextracellularcalciuminfluxandintracellularcalciumrelease.OurfindingssuggestthatDDPHhasavasodilativeeffectbothinvivoandinvitro,whichmediatesaneuroprotectiveeffectonischemicnervetissue.

简介：ALLHAT（AntihypertensiveandLipid-LoweringtreatmenttopreventHeartAttackTrial，应用抗高血压和降脂治疗预防心脏病发作研究）是在美国进行的一项前瞻性，随机，双盲，活性药物平行对照试验，始于1994年，共入选了42418名高危高血压患者，黑人占35％，比较了ACE抑制剂（赖诺普利）、钙拮抗剂（络活喜）、α受体阻滞剂与利尿剂（氯噻酮）对终点事件的影响。ALLHAT试验的主要终点是冠心病死亡或非致死性心肌梗死，次要终点是总死亡率、卒中、冠心病联合终点和心血管疾病联合终点。